Skip to main content


Latest articles

28-09-2020 | Rheumatology | News | Article

Meta-analysis points to increased diabetes risk in people with rheumatoid arthritis

Findings from a meta-analysis presented at the virtual 56th EASD Annual Meeting suggest that patients with rheumatoid arthritis have a significantly elevated risk for developing diabetes.

25-09-2020 | Rheumatology | News | Article

Molecular-based machine learning tool predicts anti-TNF response in RA

Machine learning models based on gene expression and DNA methylation profiles may accurately predict response to adalimumab and etanercept in patients with rheumatoid arthritis, research from the Netherlands shows.

24-09-2020 | Rheumatology | News | Article

Tocilizumab may delay joint damage in JIA

The majority of patients with systemic or polyarticular-course juvenile idiopathic arthritis do not develop radiographic joint progression during the first 2 years of tocilizumab treatment, research shows.

23-09-2020 | Rheumatology | News | Article

Mediterranean diet potentially reduces rheumatoid arthritis risk in women who smoke

Following the Mediterranean diet could help reduce the risk for rheumatoid arthritis among women who smoke, research findings indicate.

21-09-2020 | Rheumatology | News | Article

Even low-dose glucocorticoids raise serious infection risk in RA patients

Among patients with rheumatoid arthritis receiving stable DMARD treatment, long-term glucocorticoid use is associated with a dose-dependent increase in the risk for serious infection, with a “small but significant” risk even at the lowest doses, researchers report.

18-09-2020 | Rheumatology | News | Article

Sarilumab may improve glycemic control in people with RA, diabetes

Treatment with the IL-6 receptor inhibitor sarilumab is associated with a greater improvement in glycemic control than conventional DMARDs or adalimumab among patients with comorbid rheumatoid arthritis and diabetes, indicate findings from a post-hoc analysis.

17-09-2020 | Rheumatology | News | Article

COVID-19: High rates of medication adherence in rheumatology patients

Nonadherence to rheumatology medications during the COVID-19 pandemic is uncommon, researchers report.

16-09-2020 | Rheumatology | News | Article

Self-reported disability in early RA patients predicts all-cause mortality risk

Patients with early rheumatoid arthritis who report higher HAQ-measured disability after taking DMARDs for a year are at greater risk for all-cause mortality than those who report lower disability scores, indicate findings from the Canadian Early Arthritis Cohort.

15-09-2020 | Rheumatology | Highlight | Article

Tocilizumab shows lung benefits in early SSc

Tocilizumab does not significantly improve skin fibrosis in patients with diffuse cutaneous systemic sclerosis but may preserve lung function among individuals with early interstitial lung disease, say researchers.

14-09-2020 | Rheumatology | News | Article

Cardiovascular damage apparent in early RA

Individuals with treatment-naïve early rheumatoid arthritis show evidence of cardiovascular disease that improves following initiation of DMARD therapy, UK research shows.

11-09-2020 | Rheumatology | News | Article

‘Gaps in knowledge’ on DMARD use and fertility in RA patients highlighted

The authors of a systematic review report that DMARD treatment does not seem to have a detrimental impact on fertility in patients with rheumatoid arthritis, but limited evidence means that more research is needed.

10-09-2020 | Rheumatology | News | Article

Maximal improvement in fatigue lags behind remission in RA patients

Fatigue among patients with early rheumatoid arthritis improves significantly following the initiation of DMARDs, but maximal improvements may not occur until 6 months after remission, research shows.

09-09-2020 | Rheumatology | News | Article

Preliminary results support further investigation of type I IFN inhibitor for SLE

The type I interferon inhibitor JNJ-55920839 is well tolerated and has demonstrated preliminary efficacy against systemic lupus erythematosus in a phase 1 trial, researchers report.

08-09-2020 | Rheumatology | News | Article

Cancer risk factors described for patients with SLE

Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.

07-09-2020 | Rheumatology | News | Article

Anti-CarbV antibodies show treatment biomarker potential in RA

Anti-carbamylated vimentin antibodies may be associated with treatment response and structural damage progression among patients with rheumatoid arthritis, shows a post-hoc analysis of data from the phase 3 RA-BEGIN trial.

04-09-2020 | Rheumatology | News | Article

COVID-19: Strict adherence to social isolation rules may mask the risk in RMD patients

Patients with rheumatic and musculoskeletal diseases are almost twice as likely to adhere to COVID-19 social distancing regulations as the general population, suggests research conducted in the Netherlands.

03-09-2020 | Rheumatology | News | Article

No increase in lymphoma risk with biologic treatment in RA

Treatment with biologic DMARDs does not elevate the risk for lymphoma among patients with rheumatoid arthritis, report researchers from the ARTIS study group.

02-09-2020 | Rheumatology | News | Article

Abatacept, TNF inhibitors linked to reduced CVD risk in RA

A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.

01-09-2020 | Rheumatology | News | Article

Research highlights gender disparities in academic rheumatology

Women are less likely than men to hold senior academic rheumatology positions and are under-represented as senior authors of published research articles, suggest findings from two studies published in Arthritis & Rheumatology.

28-08-2020 | Rheumatology | News | Article

Tocilizumab associated with improved outcomes in patients with COVID-19

Treatment with the IL-6 receptor inhibitor tocilizumab may be associated with a reduction in time on mechanical ventilation, shorter hospital stay, and decreased mortality risk among patients with severe COVID-19, suggest findings from three studies.

Image Credits